Neomycin and Polymyxin B Sulfates and Dexamethasone

Neomycin and polymyxin B sulfates and dexamethasone is a triple-combination ophthalmic medication that pairs two antibiotics with a corticosteroid to treat eye conditions where both infection and inflammation are present. Sold under brand names like Maxitrol and available as generic drops or ointment, the formulation is one of the most widely prescribed combination eye products in clinical practice. The rationale for bundling all three into a single preparation is straightforward, but the side-effect profile and appropriate use are more complicated than the simple label suggests.

What the Three Ingredients Actually Do

Each ingredient handles a different piece of the problem. Neomycin is an aminoglycoside antibiotic that works by interfering with bacterial protein production, effectively killing a range of gram-positive organisms and some gram-negative ones. Polymyxin B takes a different approach entirely: it targets bacterial cell membranes and disrupts them, which is lethal to many gram-negative bacteria that neomycin alone might not reach.¹ Together, the two antibiotics cover a broader bacterial spectrum than either would alone.

Dexamethasone, the third ingredient, is a potent synthetic corticosteroid. It suppresses the inflammatory cascade that produces redness, swelling, and discomfort. On its own, dexamethasone would do nothing about the bacteria causing an infection, and using it alone on an infected eye could actually make things worse by dampening the immune response. The antibiotics are there to handle the bacteria while the steroid calms the inflammation.

When It Gets Prescribed

The combination is typically used for conditions where bacterial infection and inflammation overlap or where there is a high risk of infection in an already inflamed eye. Chronic blepharitis (inflammation of the eyelids) and bacterial conjunctivitis are common reasons for a prescription. A study of 111 patients with bacterial blepharitis or conjunctivitis found that Maxitrol was more effective for bacterial control and overall therapeutic outcome than dexamethasone alone, confirming that the antibiotics contribute meaningfully beyond what the steroid achieves on its own.²

Post-surgical use is the other major category. After cataract surgery, for example, the eye is vulnerable to both infection and post-operative inflammation. A randomized trial comparing Maxitrol to a different steroid-antibiotic combination (fluorometholone with gentamicin) after cataract surgery found that both treatments controlled intraocular inflammation equally well. Patients and doctors judged the two treatments equivalent in overall success and tolerability, though the fluorometholone-gentamicin combination proved slightly better at reducing bacterial counts on the eye surface.³

Other prescribing situations include anterior uveitis with a suspected bacterial component, post-operative care after other types of eye surgery, and inflammatory conditions of the cornea where secondary infection is a concern. Doctors sometimes also prescribe it for styes or chalazia that have an infectious element, though simpler treatments often come first for those conditions.

Allergic Reactions and Neomycin Sensitivity

Neomycin is one of the more allergenic antibiotics in common use, and this is probably the most underappreciated risk of the combination. Allergic contact dermatitis to neomycin shows up as redness, swelling, itching, and sometimes weeping skin around the eyes, which can look confusingly similar to the condition being treated. A prospective study of 522 patients who received the neomycin-polymyxin B-dexamethasone ointment after periocular surgery found that about 1.5% developed confirmed allergic contact dermatitis, with reactions appearing anywhere from three to fourteen days after starting the medication.⁴

That 1.5% rate may sound small, but it becomes more significant when you consider how many prescriptions are written. And reactions can be much more severe than localized dermatitis. A case report documented a patient who developed a severe, generalized hypersensitivity reaction after receiving Maxitrol eye drops following cataract surgery. That patient had a known previous allergic reaction to neomycin, which highlights a simple but frequently overlooked precaution: anyone with a history of neomycin allergy should not receive this combination at all.⁵

The tricky part is that many people do not know they are sensitive to neomycin. It is found in over-the-counter products like Neosporin and various first-aid ointments. Someone who has noticed skin irritation after using an antibiotic ointment on a cut may actually have a neomycin allergy without ever being formally diagnosed. If you have ever reacted to a topical antibiotic cream, mention it to your eye doctor before starting any neomycin-containing eye drop.

Steroid Risks That Build with Time

Dexamethasone is one of the more potent ophthalmic corticosteroids, and its inclusion in this combination means that prolonged use carries real risks even though the antibiotic ingredients are relatively benign in short courses. The two primary concerns are elevated intraocular pressure and cataract formation.

The link between topical corticosteroid eye drops and pressure spikes inside the eye has been recognized since the early 1960s, when researchers demonstrated that dexamethasone eye drops could reproducibly raise intraocular pressure in study subjects, with the effect disappearing when the drops were stopped and returning when they were restarted.⁶ A systematic review confirmed that the risk increases with prolonged use, frequent dosing, younger age, and higher anti-inflammatory potency of the steroid, and dexamethasone sits near the top of the potency scale.⁷ Sustained high intraocular pressure can damage the optic nerve and lead to steroid-induced glaucoma, a condition that is essentially preventable by monitoring and limiting how long the drops are used.

Cataracts are the second long-term concern. Research into glucocorticoid-induced cataracts shows that over half of patients receiving systemic corticosteroids for more than sixty days develop some form of ocular complication, with cataract formation being the most common at roughly 36% and glaucoma at about 16%.⁸ Those numbers come from systemic steroid use, and topical eye drops deliver a smaller total dose, but the lens sits right in the path of the medication. Ophthalmologists generally aim to keep steroid-containing eye drop courses as short as possible, usually one to two weeks, and schedule follow-up visits to check pressure if longer use is needed.

The practical upshot: if your doctor prescribes this combination, use it for the length of time specified and no longer. Keeping leftover drops and reusing them for a future flare-up without medical guidance is a recipe for the slow pressure creep that leads to steroid-related complications.

Neomycin and Corneal Surface Effects

Separate from allergic reactions, neomycin has some direct toxicity to corneal epithelial cells, the thin layer of cells that forms the eye’s outermost surface. In vitro studies using corneal cell cultures found that neomycin caused significant inhibition of cell viability at certain concentrations, even after relatively short exposure times.⁹ That said, a comparison of various topical antibiotic solutions found that the neomycin-polymyxin B combination had relatively little effect on corneal epithelial wound healing rates and the quality of healing compared to other tested antibiotics.¹⁰

These two findings are not contradictory. At clinical concentrations used in short courses, the combination appears to be reasonably well-tolerated on the corneal surface. The concern grows with extended or heavy use, particularly in eyes that already have compromised epithelium from injury, surgery, or dry eye disease. In those situations, ophthalmologists sometimes opt for alternative antibiotic-steroid combinations that avoid neomycin altogether.

Situations Where This Combination Should Be Avoided

The most important contraindication is active viral eye infection, particularly herpes simplex keratitis. The dexamethasone component suppresses the local immune response, which can allow a herpes virus to replicate more aggressively. Corticosteroids in the context of herpes simplex keratitis are described as a double-edged sword: they help prevent inflammatory damage but make it harder to clear actively replicating virus. In a study of herpes stromal keratitis, while the steroid group had significantly less treatment failure than placebo (26% versus 73%), the rate of dendritic keratitis recurrence was higher in the steroid group (7% versus 2%), illustrating the tradeoff.¹¹ In that study, steroids were used under carefully controlled conditions with concurrent antiviral treatment. For a general prescription of the neomycin-polymyxin B-dexamethasone combination, herpes simplex keratitis is a clear reason not to prescribe.

Fungal eye infections are another contraindication. Steroids can worsen fungal keratitis dramatically, and neither neomycin nor polymyxin B has any antifungal activity. If a fungal cause is suspected, this combination is worse than useless because it actively aids the pathogen while providing no treatment for it. Patients with known or suspected tuberculosis of the eye, vaccinia infections, or other viral diseases of the cornea and conjunctiva should similarly avoid this product.

People with a perforated eardrum should not use the otic (ear) formulation of this combination, since the neomycin can reach the inner ear and cause hearing damage. This matters because the same medication is available in both ophthalmic and otic forms, and patients sometimes confuse the two.

How Bacterial Resistance Affects the Picture

A reasonable question about any antibiotic product that has been on the market for decades is whether bacteria have developed resistance to it. The data here is actually somewhat reassuring for neomycin specifically. A study of bacterial isolates from corneal infections at a major eye center in South China found that neomycin resistance rates were the lowest among the five tested antibiotics that have eye drop formulations. Resistance among gram-positive isolates was about 8%, and among gram-negative isolates about 10%, compared to chloramphenicol resistance rates of 34% and 60% for the same groups.¹²

Polymyxin B resistance does exist, and it typically arises through modifications to the lipopolysaccharide molecules in bacterial outer membranes, effectively changing the target the drug needs to bind.¹³ In the context of topical ophthalmic use, this resistance is less concerning than it is in systemic medicine, where polymyxins serve as drugs of last resort for multidrug-resistant infections. The concentrations delivered directly to the eye surface are far higher than what bacteria encounter from intravenous dosing, which can overcome some resistance mechanisms.

Still, resistance patterns vary by region and change over time. What holds true in one country may not apply in another, and the data from any single center should not be taken as universally valid. The broader point is that, for now, the antibiotic ingredients in this combination remain reasonably effective against the bacteria most commonly involved in external eye infections.

Why Treatment for Chronic Blepharitis Involves More Than Just Drops

Chronic blepharitis is one of the most common reasons this combination gets prescribed, and it is worth understanding that drops alone rarely solve the problem. A comparative study of different treatment approaches for chronic blepharitis found that groups receiving more comprehensive regimens, including lid hygiene measures alongside medication, showed significant improvement across all measured signs and symptoms. The group relying on a simpler approach saw no meaningful improvement in itching, dry eye, eyelash loss, or eyelid-margin redness.¹⁴

This aligns with what most ophthalmologists will tell you: a medicated drop addresses the acute flare, but without consistent lid hygiene (warm compresses, lid scrubs, sometimes omega-3 fatty acid supplementation), the condition tends to recur as soon as the drops are stopped. The neomycin-polymyxin B-dexamethasone combination can break the cycle of infection and inflammation, but it is not intended to be a permanent maintenance therapy given the steroid risks described earlier.

Veterinary Use and Unique Animal Risks

This same triple-combination product is widely prescribed in veterinary ophthalmology for dogs and cats, treating many of the same conditions: conjunctivitis, blepharitis, and post-surgical inflammation. However, animals can develop complications that differ from those seen in humans. A case series documented six dogs that developed punctal stenosis, a narrowing or closure of the tear drainage openings, after long-term use of topical neomycin-polymyxin B-dexamethasone. The onset ranged from four months to over a year of treatment, and the condition presented as excessive tearing with fibrotic tissue visible over the puncta.¹⁵

Cats face a different and more alarming risk. A review of 61 cats that experienced anaphylactic events within four hours of receiving ophthalmic antibiotic preparations found that products containing bacitracin, neomycin, and polymyxin B accounted for 44% of cases, while oxytetracycline and polymyxin B combinations accounted for another 21%.¹⁶ The ophthalmic antibiotics were most commonly being given for conjunctival or corneal disease. True anaphylaxis from an eye drop is rare even in cats, but veterinarians who work with felines are generally aware of the risk and may choose alternative medications when possible.

If your vet prescribes a neomycin-polymyxin B-dexamethasone product for your pet, the same general principles apply as for humans: use it for the prescribed duration, watch for signs of allergic reaction (swelling around the eye, pawing at the face, or in cats any sign of respiratory distress), and do not extend the course without veterinary guidance. The steroid-related pressure and cataract risks apply to animal eyes just as they do to human ones, though dogs are thought to be somewhat less susceptible to steroid-induced pressure spikes than people.